Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
47.31
-0.28 (-0.59%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bristol-Myers Squibb
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
45
46
Next >
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
February 06, 2024
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy.
Via
Benzinga
Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
February 06, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Bristol-Myers Squibb Options Trading: A Deep Dive into Market Sentiment
February 05, 2024
Via
Benzinga
Undervalued Gems: 7 Stocks Set for a Major Rebound
February 05, 2024
Each of these seven undervalued stocks has fallen by 25% or more from its 52-week high, but may have a path back to prior prices.
Via
InvestorPlace
3 Blue Chip Dividend Stocks To Play Defense
February 02, 2024
We will discuss 3 long-term blue chip stocks to play defense. They have raised their dividends each year for over ten years, have current yields above the S&P 500 Index average, and should continue to...
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Bristol-Myers Squibb's Earnings Outlook
February 01, 2024
Via
Benzinga
Is Bristol Myers Squibb Stock a Buy Now?
January 25, 2024
This healthcare stock has seen healthier days.
Via
The Motley Fool
Uncovering Dividend Opportunities with NYSE:BMY.
January 25, 2024
Analyzing BRISTOL-MYERS SQUIBB CO (NYSE:BMY)'s Dividend Potential.
Via
Chartmill
Bristol Myers Squibb (BMY) Q4 2023 Earnings Call Transcript
February 02, 2024
BMY earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
February 02, 2024
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
February 02, 2024
The Dow led the major indexes higher. Big techs diverged on results.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
What's Going On With US Pharma Giant Bristol-Myers Squibb Stock Today?
February 02, 2024
Bristol Myers Squibb reports Q4 revenues of $11.48 billion, up 1% YoY. Eliquis and Opdivo sales drive growth, offsetting Revlimid decline.
Via
Benzinga
Bristol Myers Shares Rise On Fourth-Quarter Earnings Beat
February 02, 2024
Bristol Myers earnings came in above expectations, although Opdivo sales were slower than expected. BMY stock gained.
Via
Investor's Business Daily
Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year
February 02, 2024
Stock futures are pointing upwards on Friday as traders assess earnings reports from Meta Platforms, Inc.
Via
Benzinga
Earnings Scheduled For February 2, 2024
February 02, 2024
Companies Reporting Before The Bell • W.W. Grainger (NYSE:GWW) is likely to report quarterly earnings at $8.05 per share on revenue of $4.04 billion.
Via
Benzinga
Investor Optimism Improves Following Earnings, Economic Reports; Dow Jumps Over 350 Points
February 02, 2024
The CNN Money Fear and Greed index showed an increase in the overall market sentiment, but the index remained in the "Greed" zone on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Amazon, Apple And 3 Stocks To Watch Heading Into Friday
February 02, 2024
With U.S. stock futures trading mostly higher this morning on Friday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
BMY Stock Dividend Delight: A Blue-Chip’s Healthy Yield
January 31, 2024
In the grand theater of the financial markets, Bristol-Myers Squibb stands out as a robust performer. Despite the recent pullback, the market sentiment towards this biopharmaceutical titan remains...
Via
Talk Markets
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
January 30, 2024
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions.
Via
Benzinga
Did You Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts?
January 30, 2024
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients
January 29, 2024
Results from Bristol Myers Squibb's Phase 3 CheckMate -67T trial on subcutaneous Opdivo (nivolumab) for advanced clear cell renal cell carcinoma. Noninferiority compared to IV Opdivo.
Via
Benzinga
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
January 29, 2024
--News Direct--
Via
News Direct
3 Healthcare Stocks at 52-Week Lows: Buy or Bye?
January 26, 2024
Investors should consider picking up these healthcare stocks at 52-week lows to benefit from their potential rebound.
Via
InvestorPlace
Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of "Risks Of Secondary Cancer'
January 24, 2024
FDA issues classwide black box warning for CAR-T therapies due to T-cell cancer risk. Drops Gilead's cell therapy from the list.
Via
Benzinga
Exposures
Product Safety
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
January 29, 2024
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
7 Beaten-Down Value Stocks Poised for an Epic Turnaround
January 23, 2024
Battered value stocks could be priced for an epic rebound in 2024 and beyond. These seven can quickly escape Wall Street's penalty box.
Via
InvestorPlace
Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study
January 23, 2024
Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial.
Via
Benzinga
Bristol Myers Squibb's Combo Therapy Shows Sustained Benefits Over Pfizer's Cancer Drug In Kidney Cancer Patients After 8 Years Of Followup
January 23, 2024
Bristol Myer's Opdivo/Yervoy's long-term survival benefits in CheckMate-214 trial for advanced renal cell carcinoma. Significant reductions in risk of death, improved OS, PFS, and ORR after eight...
Via
Benzinga
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
January 23, 2024
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.
Via
Benzinga
Exposures
Product Safety
Bristol Myers' Lead Cancer Immunotherapy Shows Progression Free Survival Versus Chemo In Certain Type Of Colorectal Cancer
January 22, 2024
Bristol Myers' Opdivo + Yervoy combo shows 79% reduced risk in MSI-H/dMMR metastatic colorectal cancer.
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
45
46
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.